National Cancer Center

National Cancer Center Announces Recipients of 2022-23 Research Fellowship Awards

Retrieved on: 
Thursday, June 30, 2022
Science, Other Philanthropy, Research, Oncology, Health, Philanthropy, Fund Raising, Foundation, Melanoma, Diagnosis, New York University Grossman School of Medicine, University of Nebraska Medical Center, Rockefeller University, Research, Harvard Medical School, Icahn School of Medicine at Mount Sinai, National Cancer Center, Death, Man, Nebraska Medicine, NCC, Cancer, Brain, University of Pittsburgh, University of California, PAP, Prostate cancer, Coronavirus Scientific Advisory Board (Turkey), UPMC Hillman Cancer Center, Woman, Therapy, Dana–Farber Cancer Institute, Education, University, Cleveland Clinic, Duke University Hospital, City, DNA, Cervical cancer, McMaster University Medical School, Johns Hopkins School of Medicine, Time, DNA repair, Massachusetts General Hospital, Interferon, Baylor College of Medicine, Pharmaceutical industry, Management, Medicine, Doctor of Philosophy

The National Cancer Center is pleased to announce the recipients of its 2022-23 research grant awards, which support research fellows pursuing promising and innovative cancer research.

Key Points: 
  • The National Cancer Center is pleased to announce the recipients of its 2022-23 research grant awards, which support research fellows pursuing promising and innovative cancer research.
  • This growing public support also enabled National Cancer Center to increase the size of its awards by a significant margin.
  • National Cancer Centers mission is to fill an often-overlooked role in the quest to cure cancer by identifying and funding promising projects by the best up-and-coming research fellows, said Regina English, Executive Director of the National Cancer Center.
  • National Cancer Center was founded by Dr. J. Ernest Ayre in 1953 as a non-profit organization committed to research and education about cancer.

Berry Oncology launches HIFI Pan-Cancer Screening, a multi-cancer early screening product for detecting six high-risk cancers at one time

Retrieved on: 
Thursday, June 23, 2022
Qiming Venture Partners, Solution, Industry, Public health, Central committee, Overalls, Environment, Technology, Compliance, Hospital, Survival rate, WGS, Research, CEO, Survival, International Agency for Research on Cancer, Stomach, Recurrence, Liver cancer, HIFI, Pancreatic cancer, DNA, Nucleic acid thermodynamics, Colorectal cancer, Ecosystem, NGS, Quality of life, National Cancer Center, Esophageal cancer, Whole genome sequencing, University, State Council, Lung cancer, Patient, Organic, Communist party, Medicine, IARC, Diagnosis, Genetic testing, Awareness, Central China, Chinese Academy of Sciences, Chinese Academy of Medical Sciences COVID-19 vaccine, Goal, Mobile phone, Medical imaging, Cancer

HIFI Pan-Cancer Screening is the first early screening product for multiple cancer types using whole genome sequencing (WGS) of cell-free DNA (cfDNA) worldwide.

Key Points: 
  • HIFI Pan-Cancer Screening is the first early screening product for multiple cancer types using whole genome sequencing (WGS) of cell-free DNA (cfDNA) worldwide.
  • The self-iterative HIFI technology platform can reduce the costs of product development and testing services, and thus making early screening for multiple cancers more affordable.
  • The launch of the multi-cancer early screening product will further reinforce Berry Oncology's leadership in the early screening sector."
  • Moving forward, Berry Oncology will continue to optimize its technology system and iterate early screening products to deliver more advanced early cancer screening solutions in accordance with the actual market demand and environment.

Fujitsu and Southern Tohoku General Hospital start joint research on AI technology for detecting pancreatic cancer from non-contrast CT scans

Retrieved on: 
Monday, April 25, 2022
Neutron, Pancreas, Cancer, Laboratory, Neutron capture therapy of cancer, Social, Proton therapy, BNCT, Research, Diagnosis, Pancreatic cancer, Health promotion, ICT, Medicine, Healthy Living, Hospital, Humanities, Patient, SVP, Radiology, FCOM, Technology, QOL, Human body, US, CT, Solution, Sudan Journal of Medical Sciences, AI, National Cancer Center, Neoplasm, Fujitsu, Cyst, Quality of life, Knowledge, Medical imaging

The new AI technology has been trained with data from 300 anonymized CT images of pancreatic cancer patients provided by the Southern Tohoku General Hospital and offers an optimal image analysis method based on the shape of organs and cancer tumors.

Key Points: 
  • The new AI technology has been trained with data from 300 anonymized CT images of pancreatic cancer patients provided by the Southern Tohoku General Hospital and offers an optimal image analysis method based on the shape of organs and cancer tumors.
  • The joint research project represents a new approach to apply AI technology to support medical practitioners in detecting early signs of pancreatic cancer from CT scans.
  • Fujitsu and the Southern Tohoku General Hospital will conduct clinical trials within this joint research to further improve the newly developed AI and offer a technology for an early detection of pancreatic cancer that can help to improve the quality of life of each patient.
  • Fujitsu will continue research and development on converging technologies(5) that combine AI-powered image analysis technology with Southern Tohoku General Hospital's medical knowledge in pancreatic cancer treatment, with the aim of establishing AI technology able to support the early detection of pancreatic cancer."

Stop & Shop Kicks Off Annual ‘Help Cure Childhood Cancer’ Campaign

Retrieved on: 
Thursday, April 7, 2022
Roswell Park Comprehensive Cancer Center, Stop & Shop, National Cancer Institute, Adult, Research, Hospital, Boston Red Sox, MD, Technology, Twitter, GLOBE, Pan-Mass Challenge, Education, The Jimmy Fund, Nursing, National Cancer Center, Pediatrics, Dana–Farber Cancer Institute, Brain, Hope, Delhaize Group, Child, Department, Memorial Sloan Kettering Cancer Center, Stop, Young adult, Doctor of Philosophy, Malignancy, Health, Instagram, Patient, Partnership, Hunger, Adolescence, MSK, News, Cancer, Empower, 2009 Boston Red Sox season, Physician, Pharmaceutical industry, Medicine, Toy

QUINCY, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Stop & Shop today announced the start of its annual Help Cure Childhood Cancer campaign to support Dana-Farber Cancer Institute and the Jimmy Fund in Massachusetts and MSK Kids , the Pediatric Program at Memorial Sloan Kettering Cancer Center in New York.

Key Points: 
  • QUINCY, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Stop & Shop today announced the start of its annual Help Cure Childhood Cancer campaign to support Dana-Farber Cancer Institute and the Jimmy Fund in Massachusetts and MSK Kids , the Pediatric Program at Memorial Sloan Kettering Cancer Center in New York.
  • Stop & Shops Help Cure Childhood Cancer campaign will run in-stores from April 1 through April 30.
  • Every year, we look forward to our customers and associates' participation in helping us raised funds for pediatric cancer research and care, said Stop & Shop President, Gordon Reid.
  • The Stop & Shop Pediatric Brain Tumor Clinic at Dana-Farber Cancer Institute is a world-renowned destination for children with malignant and nonmalignant brain tumors.

Scientists Discover Gene Mutation That Signals Aggressive Melanoma

Retrieved on: 
Thursday, April 7, 2022
NEW, National Cancer Institute, No, Rehabilitation, Research, Color, Mount Sinai Hospital, Hospital, Chromatin, Neoplasm, Journal of Neurology, Neurosurgery, and Psychiatry, Skin cancer, Twitter, U.S. News & World Report, Community, Mount Sinai Hospital (Manhattan), Health system, Disease, Mutation, Urology, Mount Sinai Health System, Health, Cell Reports, Brain, Honors student, National, DNA, Gene expression, Melanoma, Doctor of Philosophy, World, Mount Sinai Kravis Children's Hospital, Patient, Cell, Skin, News, Icahn School of Medicine at Mount Sinai, National Institutes of Health, Purdue University, National Cancer Center, Physician, YouTube, Newsweek, Vaccine, Medical imaging, Geriatrics, New York University, Medicine, ARID2, Orthopedic surgery, Ophthalmology, Facebook

NEW YORK, April 7, 2022 /PRNewswire-PRWeb/ -- Mutation of a gene called ARID2 plays a role in increasing the chance that melanoma, a deadly skin cancer, will turn dangerously metastatic, Mount Sinai researchers report.

Key Points: 
  • Mutation of a gene called ARID2 plays a role in increasing the chance that melanoma, a deadly skin cancer, will turn dangerously metastatic, Mount Sinai researchers report.
  • NEW YORK, April 7, 2022 /PRNewswire-PRWeb/ -- Mutation of a gene called ARID2 plays a role in increasing the chance that melanoma, a deadly skin cancer, will turn dangerously metastatic, Mount Sinai researchers report.
  • The findings suggest that patients whose melanoma tumors have an ARID2 mutation may have a more aggressive cancer and may need to be treated differently, according to a study published in Cell Reports in April.
  • In this study, scientists used melanoma tumor models to measure the role of the ARID2 gene in cancer progression.

National Cancer Center Japan Joins Caris' Precision Oncology Alliance

Retrieved on: 
Thursday, February 10, 2022
RNA, WES, Artificial intelligence, Precision medicine, Exome, American Securities, Protein, Sequence, Research, FACP, Twitter, Ministry, Cancer, National Cancer Center, Ministry of Health and Welfare, POA, Patient, Diagnosis, Blood, DNA, WTS, Physician, Intelligence, Drug development, Database, Disease, Partnership, NCC, Education, MBA, Pharmaceutical industry, Medical imaging, Dentistry, Health, Gastroenterology

IRVING, Texas, Feb. 10, 2022 /PRNewswire/ -- Caris Life Sciences (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that the National Cancer Center (NCC) Japanhas joined Caris' Precision Oncology Alliance (POA).

Key Points: 
  • IRVING, Texas, Feb. 10, 2022 /PRNewswire/ -- Caris Life Sciences (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that the National Cancer Center (NCC) Japanhas joined Caris' Precision Oncology Alliance (POA).
  • Established in 1962 by Japan's Ministry of Health and Welfare, NCC Japan leads the nation's cancer treatment, prevention, control, research and education.
  • The Caris Precision Oncology Alliance includes 59 cancer centers and academic institutions.
  • The National Cancer Center Japan, established in 1962, is a leading medical institution in cancer treatment and research in Japan.

Oklahoma Cannabis Brand Chef Joey's Premium Edibles Announces Partnership with Children's Hospital Foundation for "Kisses for Cancer" Fundraising Initiative

Retrieved on: 
Friday, January 28, 2022
Awareness, Family, Cancer pain, Patient, Face, LLC, Timeline of cannabis laws in the United States, National Cancer Center, Research, Instagram, Partnership, Cannabinoid, Hospital, Health, BC Children's Hospital Foundation, Education, CHF, Medicine, Toy, Cancer

"Children's Hospital Foundation is grateful to partner with the JDMG Family to raise funds for pediatric cancer during the month of February," said Kathy McCracken, Executive Director of Children's Hospital Foundation.

Key Points: 
  • "Children's Hospital Foundation is grateful to partner with the JDMG Family to raise funds for pediatric cancer during the month of February," said Kathy McCracken, Executive Director of Children's Hospital Foundation.
  • Chief Executive Officer of JDMG, LLC, Dallas Owens, said "We are honored to be able to play a role in assisting Children's Hospital Foundation.
  • About JDMG, LLC: JDMG, LLC and the Delta Oil Co. family of brands including Chef Joey's Premium Edibles, Delta Oil Co. and Body Guac were established in Tulsa, Oklahoma in 2020.
  • To learn more about Children's Hospital Foundation visit, Oklahoma Children's Hospital Foundation ( chfkids.com ).

Legends for Charity® honors Erin Andrews with prestigious Pat Summerall Award during Super Bowl week, charity event benefits St. Jude Children's Research Hospital

Retrieved on: 
Tuesday, January 25, 2022
CDC, National Cancer Institute, Survival, Research, St. Jude Children's Research Hospital, Ocean Productions, Love, Hope, FOX, Zane, Legend, Travel, Safety, CEO, Female, Sport, Acute lymphoblastic leukemia, Instagram, NCI-designated Cancer Center, Health, NFL, Housing, ALSAC, Indian Telly Awards, Florida Gators, Charity, Heart, Hospital, Food, Multimedia, National Cancer Center, Cancer, TikTok, PAT, Twitter, Child, Friends, Fox Sports, Awareness, Medicine, Toy, Facebook, Jude the Apostle

"It is a tremendous honor to be the first female recipient of the coveted Pat Summerall Award," said Andrews.

Key Points: 
  • "It is a tremendous honor to be the first female recipient of the coveted Pat Summerall Award," said Andrews.
  • To receive this award at this dinner that benefits St. Jude Children's Research Hospital, a charitable organization near and dear to my heart will make this evening that much more special."
  • Andrews first visited St. Jude Children's Research Hospital in Memphis, Tennessee, in 2013, where she met St. Jude patient Zane and they bonded over their shared love for the Florida Gators.
  • Legends for Charityis an annual national event held during Super Bowl Weekend to present The Pat Summerall Award to a deserving broadcaster.

Bold Therapeutics Extends South Korea Option Agreement for BOLD-100, a First-in-Class Anti-Resistance Therapeutic

Retrieved on: 
Thursday, January 13, 2022
GRP78, Stomach, National Cancer Center, Samsung Medical Center, Reactive oxygen species, Unfolded protein response, Cancer, Douglas BTD Destroyer, CEO, ROS, UPR, DNA, Therapy, Odds, Seoul National University Hospital, DNA repair, Induced cell cycle arrest, Emphasis (typography), FOLFOX, Cell death, FDA, Pharmaceutical industry

VANCOUVER, British Columbia, Jan. 13, 2022 /PRNewswire/ --Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, is pleased to announce an extension of the option agreement with an undisclosed publicly traded South Korean biopharmaceutical company, originally executed in May 2020, for development and commercialization rights to BOLD-100 in South Korea.

Key Points: 
  • VANCOUVER, British Columbia, Jan. 13, 2022 /PRNewswire/ --Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, is pleased to announce an extension of the option agreement with an undisclosed publicly traded South Korean biopharmaceutical company, originally executed in May 2020, for development and commercialization rights to BOLD-100 in South Korea.
  • Bold Therapeutics' BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that (1) alters the unfolded protein response (UPR) through selective GRP78 inhibition; and (2) induces reactive oxygen species (ROS) which causes DNA damage and cell cycle arrest.
  • "As our partner is one of the fastest growing and most respected pharmaceutical companies in South Korea, we are honored to extend this option agreement that allows us to further leverage their substantial expertise in oncology development," said E. Russell McAllister, CEO of Bold Therapeutics.
  • For more information about Bold Therapeutics, please visit the company's website at www.bold-therapeutics.com

Enterin and Their Collaborators at NIH Announce That Alpha-Synuclein, the Culprit in Parkinson's Disease, is Core and Central to Normal Immune Function

Retrieved on: 
Tuesday, January 11, 2022
Neurodegeneration, National Cancer Institute, Association, Survival, Vaccination, Peritoneum, Immunology, Patient, Human, NIH, Central nervous system, CSO, ENS, Enteric nervous system, R gene, Macrophage, Parkinson's disease, CMO, Neutrophil, GI, GLOBE, Cell Reports, National Institute, Nervous system, Physiology, Alzheimer's disease, Obesity, Animal, National, Infection, Norovirus, Diabetes, Mouse, B cell, Lists of diseases, PD, Peritoneal cavity, National Cancer Center, Neuron, Immune system, National Institutes of Health, Alpha-synuclein, Brain, Damage-associated molecular pattern, Head, Abdominal cavity, Pharmaceutical industry, Vaccine, Disease

Although the association between S and PD was discovered almost 25 years ago, its role in normal vertebrate physiology has remained obscure.

Key Points: 
  • Although the association between S and PD was discovered almost 25 years ago, its role in normal vertebrate physiology has remained obscure.
  • Recent studies have demonstrated that the presence of a functional S gene confers survival benefit to mice infected with a neurotropic virus.
  • The authors show that the mice lacking the S gene cannot recruit immune cells to the site of infection nor induce pathogen-specific immune responses.
  • Conversely, when exogenous S is introduced into the peritoneum, both the innate and adaptive immune response is enhanced.